Fig. 8: Administration of cisplatin and hsa-miR-30a-3p significantly reduce tumor growth.

A Flowchart showing an in vivo tumor-xenograft mouse model. Luciferase-positive BC UMUC3 cells (1 × 106 cells) were injected into the bladders of SCID mice. After 1 week, the mice intravesically received twice-weekly lenti-miR-30a-3p plasmid and cisplatin (2.5 mg/kg) for 4 weeks. B, C Bioluminescent images using IVIS spectrum were performed weekly, and the luminescent intensity of photons emitted from each tumor in the images was quantified (N = 3). D Tumor images representing excised tumors from each group and histologic sections of tumor were stained with H&E. E–G IHC staining exhibited Ki-67 and LC3-II expression in murine tumor tissues (N = 3). All data are expressed as means ± SDs in triplicate samples. *P < 0.05 relative to the control group.